MedTrace Logo

Topical Calcipotriol Versus Photodynamic Therapy in the Treatment of Oral Leukoplakia

NCT07658508 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if calcipotriol and photodynamic therapy are equally effective in treatment of leukoplakia or not. The main questions it aims to answer are:

do lesions decrease or disappear when treated by calcipotriol or PDT? does the drug affect the salivary biomarkers

Participants will:

Take calcipotriol daily for 4 weeks or perform 4 PDT sessions over 4 weeks measure changes in salivary biomarkers be followed up for 3 months

Conditions

  • Oral Leukoplakia

Interventions

DRUG

Calcipotriol 0.005% gel

using prepared calcipotriol in orabase twice daily for 4 weeks

DEVICE

ALA mediated PDT

applying photodynamic therapy using laser device on photosensitizer

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Eglal M Moussa, PhD oral medicine · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2026-08-10
Completion
2026-09-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07658508 on ClinicalTrials.gov